meglumine has been researched along with Nausea in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ando, Y; Hayashi, T; Imaizumi, K; Isaji, A; Ito, K; Kawada, K; Matsuda, H; Mine, N; Miyamoto, A; Naito, K; Nakanishi, T; Okada, T; Oya, M; Sakurai, K; Shibata, T; Suzuki, E; Takahashi, H; Uyama, I; Yamada, S | 1 |
| Christensen, RE; Dillman, JR; Lai, ME; Mollard, BJ; Phan, T; Smith, EA | 1 |
| Bleicher, AG; Kanal, E | 1 |
| Durmus, T; Hamm, B; Heine, O; Maurer, M; Wagner, M; Wolf, M | 1 |
| Schütte, HE | 1 |
| Grasso, A; Gusso, MI | 1 |
| Blumenfield, DM; Blumetti, RF; Goldstein, HA; Holyoak, WL; Hugo, FP; Kashanian, FK | 1 |
2 trial(s) available for meglumine and Nausea
| Article | Year |
|---|---|
Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy.
Topics: Aged; Antiemetics; Aprepitant; Cisplatin; Esophageal Neoplasms; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Meglumine; Middle Aged; Morpholines; Nausea; Risk Factors; Stomach Neoplasms; Surveys and Questionnaires; Treatment Outcome; Vomiting | 2016 |
Safety assessment of gadopentetate dimeglumine in U.S. clinical trials.
Topics: Bilirubin; Clinical Trials as Topic; Contrast Media; Drug Combinations; Electrocardiography; Electroencephalography; Gadolinium; Gadolinium DTPA; Headache; Humans; Iron; Magnetic Resonance Imaging; Meglumine; Nausea; Organometallic Compounds; Paresthesia; Pentetic Acid; Research Design; Sorbitol; United States | 1990 |
5 other study(ies) available for meglumine and Nausea
| Article | Year |
|---|---|
MR enterography under the age of 10 years: a single institutional experience.
Topics: Administration, Oral; Child; Child, Preschool; Contrast Media; Female; Humans; Infant; Infant, Newborn; Inflammatory Bowel Diseases; Magnetic Resonance Imaging; Male; Meglumine; Michigan; Nausea; Organometallic Compounds; Prevalence; Retrospective Studies; Risk Factors; Vomiting | 2016 |
Assessment of adverse reaction rates to a newly approved MRI contrast agent: review of 23,553 administrations of gadobenate dimeglumine.
Topics: Contrast Media; Dyspnea; Humans; Magnetic Resonance Imaging; Meglumine; Nausea; Organometallic Compounds; Pennsylvania; Risk Assessment; Risk Factors; Urticaria; Vomiting | 2008 |
Tolerability and diagnostic value of gadoteric acid in the general population and in patients with risk factors: results in more than 84,000 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Comorbidity; Contrast Media; Drug-Related Side Effects and Adverse Reactions; Female; Germany; Humans; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Nausea; Organometallic Compounds; Prevalence; Risk Assessment; Risk Factors; Urticaria; Vomiting; Young Adult | 2012 |
Comparative study: Endografine (diatrizoate), Vasurix polyvidone (acetrizoate), Dimer-X (iocarmate) and Hexabrix (ioxaglate) in hysterosalpingography.
Topics: Abdomen; Acetrizoic Acid; Adult; Contrast Media; Diatrizoate; Female; Humans; Hysterosalpingography; Iothalamic Acid; Ioxaglic Acid; Meglumine; Nausea; Pain; Triiodobenzoic Acids | 1982 |
[Analysis of the symptomatological findings after sacculo-radiculography with Dimer-X (clinico-statistical study of 100 consecutive cases].
Topics: Adolescent; Adult; Aged; Confusion; Contrast Media; Diplopia; Female; Headache; Humans; Iothalamic Acid; Male; Meglumine; Middle Aged; Nausea; Neuralgia; Radiography; Sorbitol; Spinal Diseases; Spinal Nerve Roots; Tinnitus; Vertigo | 1981 |